Spyre Therapeutics, Inc. (SYRE) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Positive SPY001 Part A topline (announced 2026‑04‑13) and multiple SKYLINE/SKYWAY readouts staged across Q2–Q4 2026, alongside an upsized equity offering priced 2026‑04‑14 that extends cash runway, have pushed the stock ~50% above its 21‑day SMA; this fresh clinical win plus strong momentum make SYRE an event‑driven hot idea near term, though highly risky.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • No Revenue • Cash Burn SYRE has a strong cash-rich, low-debt balance sheet and ample liquidity, but zero revenue, persistent losses, and negative cash flow signal significant execution risk.
Price Behavior
Key Price Behavior Insights: • Strong uptrend • Breakout support • Near-term resistance Support Level: $63–$64 Resistance Level: $73.0–$73.4 SYRE has rallied strongly over the last month with higher highs and higher lows, but after a sharp run-up it may need to consolidate unless it holds the $63–$64 support area while $73.0–$73.4 remains resistance.
Sentiment & News
Key News Insights: • Strong efficacy • Large financing • Analyst upgrade Spyre Therapeutics surged on strong SPY001 ulcerative colitis data that met its primary endpoint, prompting a sharp re-rating, a $463.5M financing, and higher analyst targets.
AI Summary
SYRE has shifted from a speculative pre-commercial biotech to a catalyst-driven re-rating candidate after the SPY001 ulcerative colitis signal, but the stock now hinges on whether upcoming 2026 readouts and continued clinical momentum can justify the valuation before dilution and execution risk catch up.
Description
Spyre Therapeutics is a preclinical biotechnology firm developing monoclonal antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its lead program is an anti-α4β7 integrin IgG1 candidate, alongside antibody programs against TL1A and IL-23 and several combination regimens currently in preclinical evaluation. The company, incorporated in 2013 and renamed from Aeglea BioTherapeutics in November 2023, is based in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 15 | Apr 22 | SYRE | Spyre Therapeutics, Inc. | Positive SPY001 Part A topline (announced 2026‑04‑13) and multiple SKYLINE/SKYWAY readouts staged across Q2–Q4 2026, alongside an upsized equity offering priced 2026‑04‑14 that extends cash runway, have pushed the stock ~50% above its 21‑day SMA; this fresh clinical win plus strong momentum make SYRE an event‑driven hot idea near term, though highly risky. | Closed | +5.8% |
| Feb 23 | Mar 2 | SYRE | Spyre Therapeutics, Inc. | Six clinical proof‑of‑concept readouts slated for 2026, reported cash runway into 2028 (~$757m cash/marketable securities) and a strong recent 21‑day move (~+26.8% with a one‑day +14% jump) give SYRE a clear event‑driven upside path; momentum traders can exploit this high‑risk setup ahead of Q2 SKYLINE Part A data and subsequent 2026 catalysts. | Closed | -3.8% |